文献速递母胎医学生殖医学

先天性肾上腺皮质增生症的个体化宫内治疗时代已经到来吗?

Has the Era of Individualized Intrauterine Treatment for Congenital Adrenal Hyperplasia Arrived?
PubMed 文献 · Prenat Diagn · 2025-01-31

本研究纳入20个有25%概率生育21-羟化酶缺陷症患儿的家庭,通过靶向测序和家系连锁分析构建单倍型,结合相对单倍型剂量与贝叶斯因子推断胎儿基因型,实现先天性肾上腺皮质增生症的无创产前诊断,并对受累女性胎儿进行宫内治疗。无创产前诊断首检成功率为90%(18/20),报告率为95%(19/20),准确率为100%(19/19);个体化宫内治疗避免了88.9%(8/9)未受累女性胎儿的不必要治疗。

要点

  • 无创产前诊断首检成功率90%(18/20),报告率95%(19/20),准确率100%(19/19)。
  • 个体化宫内治疗避免88.9%(8/9)未受累女性胎儿的不必要治疗。
  • CAH16新生儿接受宫内治疗后未见明显男性化。

核心结论

  • 无创产前诊断对21-羟化酶缺陷症家庭的早期治疗和妊娠临床管理具有深远意义。

研究设计与样本

  • 纳入20个有25%概率生育21-羟化酶缺陷症患儿的家庭,基于靶向测序和家系连锁分析构建单倍型,采用相对单倍型剂量联合贝叶斯因子推断胎儿基因型,并行侵入性产前诊断验证无创产前诊断的可靠性;对受累女性胎儿进行宫内治疗直至分娩。

主要发现

  • 无创产前诊断成功识别1例受累女性胎儿、4例受累男性胎儿、9例杂合子和5例正常胎儿。
  • 无创产前诊断首检成功率为90%(18/20),报告率为95%(19/20),准确率为100%(19/19)。
  • 个体化宫内治疗避免了88.9%(8/9)未受累女性胎儿的不必要治疗。
  • CAH16新生儿接受宫内治疗后未见明显男性化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Congenital adrenal hyperplasia (CAH) is a common metabolic genetic disease. Early diagnosis and intervention are crucial to improve the prognosis. Noninvasive prenatal diagnosis (NIPD) is an early, safe, and accurate method. This study aimed to evaluate the NIPD of CAH while guiding individualized intrauterine treatment. METHODS: Twenty families with a 25% risk of having a baby with 21-hydroxylase deficiency (21-OHD) were included. Haplotypes were constructed based on targeted sequencing and family linkage analysis. Relative haplotype dosage (RHDO) combined with Bayes factor was used to infer fetal genotypes. Invasive prenatal diagnosis was performed to verify the reliability of NIPD. For affected-female fetuses, intrauterine treatment was applied until delivery. RESULTS: In 20 families, NIPD successfully identified one female-affected fetus, four male-affected fetuses, nine heterozygotes, and five normal fetuses. The first-pass success rate of NIPD was 90% (18/20), the reporting rate was 95% (19/20), and the accuracy was 100% (19/19). Individualized intrauterine treatment avoided 88.9% (8/9) of unnecessary treatment of unaffected female fetuses. Moreover, no significant virilization was observed in the newborn of CAH16, which underwent intrauterine treatment. CONCLUSION: NIPD has far-reaching implications for the early treatment and clinical management of pregnancy in families with 21-OHD.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Fu X, Xia Y, Li S, et al. Has the Era of Individualized Intrauterine Treatment for Congenital Adrenal Hyperplasia Arrived? Prenat Diagn. 2025. PMID: 39891341. doi:10.1002/pd.6747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。